6Fisher B,Bryant J,Welmark N. Effect of p re-operative chemot herapy on the outcome of woman with breast cancer:findings from NSABPB218[J].Journal of Clinical Oncology,1997.2488.
4Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [ J ] . Cancer, 2007, 109(1): 25-32.
5Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence [ J ] . Clin Cancer Res, 2007, 13(15):4429-4434.
6Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer [ J ] . Lancet, 2003, 362(9381): 362-369.
7Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours [ J ] . Nature, 2000, 406(6797): 747- 752.
8Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets [ J ] . Proc Natl Acad Sci USA, 2003, 100(14): 8418- 8423.
9Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy [J ] . Clin Cancer Res, 2005, 11(16): 5678- 5685.
10Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [ J ] . Clin Cancer Res, 2007, 13(8): 2329-2334.
